{
  "total_samples": 200,
  "topics": {
    "Obesity / metabolic surgery": 1,
    "Long COVID mechanisms": 1,
    "Liver-directed gene therapy for hemophilia": 1,
    "Clinical trial design methodology for drug development": 1,
    "ALS": 7,
    "Alzheimer's disease": 6,
    "Microenvironment-targeting strategies": 1,
    "Huntington's disease": 5,
    "MASLD/NAFLD pathogenesis": 1,
    "CAR-T resistance mechanisms": 1,
    "Atrial Fibrillation": 6,
    "Cell therapy resistance mechanisms": 1,
    "CAR-T design in DLBCL": 1,
    "HIV antiretroviral therapy safety": 1,
    "Drug–drug interactions impacting clinical efficacy in phase III context": 1,
    "Predictors of gene therapy durability": 1,
    "HIV cure research": 1,
    "Obesity / microbiome": 1,
    "Chemotherapy resistance mechanisms (ovarian cancer)": 1,
    "Mechanisms of AAV-associated toxicity": 1,
    "CAR-T toxicity predictors": 1,
    "Rheumatoid arthritis": 6,
    "Heart Failure": 3,
    "HIV prevention (PrEP)": 1,
    "CAR-T delivery routes in solid tumors": 1,
    "Obesity inflammation": 1,
    "Endocrine therapy resistance (breast cancer)": 1,
    "AAV immunogenicity and patient selection": 1,
    "HIV/TB coinfection": 1,
    "Targeted therapy resistance (GIST)": 1,
    "Type 2 diabetes mechanisms": 1,
    "Immune-related myocarditis epidemiology": 1,
    "Coronary Artery Disease": 4,
    "CRISPR-engineered cellular immunotherapy": 1,
    "Parkinson's disease": 7,
    "HIV natural history": 1,
    "Diabetes epidemiology / environmental exposure": 1,
    "First-line immunotherapy in RCC": 1,
    "Immunotherapy epidemiology and outcomes": 1,
    "Mechanisms limiting cell therapy in solid tumors": 1,
    "Diabetes epidemiology / pregnancy": 1,
    "HIV immunotherapy": 1,
    "PD-L1 testing variability": 1,
    "Immuno-oncology phase III comparative efficacy": 1,
    "Immunotherapy outcomes modifiers": 1,
    "Genotoxicity of integrating vectors": 1,
    "Antibiotic-resistant infections (CRE)": 1,
    "Targeted therapy phase III efficacy": 1,
    "MASLD/NAFLD epidemiology / comorbidity": 1,
    "Concomitant medications and ICI efficacy": 1,
    "Host factors in immunotherapy response": 1,
    "Antibiotic-resistant infections treatment": 1,
    "Off-target assessment in ex vivo editing": 1,
    "Anticoagulant development and safety in phase III": 1,
    "Checkpoint strategies in MSI-H CRC": 1,
    "Systemic lupus erythematosus": 6,
    "Cystic fibrosis": 8,
    "Antiviral drug development and interactions": 1,
    "Coronary Artery Disease + Heart Failure": 1,
    "Coronary Artery Disease (Post-MI)": 1,
    "MASLD/NAFLD genetics": 1,
    "Diabetes prognosis / cardiorenal risk": 1,
    "Coronary Artery Disease and Heart Failure": 1,
    "ESBL infections treatment": 1,
    "Gene therapy and editing for DMD": 1,
    "Next-generation gene editing modalities": 1,
    "Cardiometabolic outcomes trials": 1,
    "MRSA/VISA mechanisms": 1,
    "ICI safety in autoimmune disease": 1,
    "MASLD/NAFLD prognosis": 1,
    "Determinants of in vivo editing response": 1,
    "Epilepsy": 6,
    "Antimicrobial stewardship": 1,
    "Obesity prognosis / weight maintenance": 1,
    "Immunology drug development (IBD)": 1,
    "Prediabetes prevention": 1,
    "Gene therapy vs molecular therapy in SMA": 1,
    "irAEs as prognostic markers": 1,
    "Macrophages in the tumor microenvironment": 1,
    "Neuroimmunology comparative phase III evidence": 1,
    "Immunotherapy (NSCLC)": 1,
    "Metabolic syndrome / dietary interventions": 1,
    "Systemic AAV adverse event epidemiology": 1,
    "MASLD/NAFLD pharmacotherapy": 1,
    "Checkpoint inhibitors in TNBC across settings": 1,
    "Oncology targeted therapy trials and biomarkers": 1,
    "Stem cell-derived neuronal transplantation": 1,
    "COVID-19 therapeutics": 1,
    "Targeted therapy (HER2 breast cancer)": 1,
    "Multiple sclerosis": 6,
    "Heart Failure (HFrEF)": 1,
    "Targeted therapy vs immunotherapy (melanoma)": 1,
    "Immunotherapy vs targeted combinations (RCC)": 1,
    "Acquired resistance to checkpoint blockade": 1,
    "Acute neurovascular trials": 1,
    "Heart Failure (HFpEF)": 1,
    "COVID-19 immunomodulators": 1,
    "Cell replacement therapy for diabetes": 1,
    "Drug–drug interaction mechanisms in oncology development": 1,
    "Cardiology phase III outcomes trials": 1,
    "Targeted therapy (ALK NSCLC)": 1,
    "COVID-19 pathogenesis": 1,
    "Immunogenicity mitigation in gene/cell therapy": 1,
    "PD-1/PD-L1 inhibitors in NSCLC": 1,
    "Resistance and subsequent therapy (EGFR NSCLC)": 1,
    "Type 2 diabetes / cardiovascular outcomes": 1,
    "Transporter-mediated drug interactions in phase III-era drugs": 1,
    "COVID-19 transmission": 1,
    "Targeted therapy biomarkers (prostate cancer)": 1,
    "Combination immunotherapy in HCC": 1,
    "Enzyme induction interactions affecting clinical trials": 1,
    "COVID-19 vaccines in immunocompromised hosts": 1,
    "Targeted therapy (cholangiocarcinoma)": 1,
    "Safety epidemiology within phase III programs": 1,
    "Diabetes / diabetic kidney disease": 1,
    "Predictive biomarkers for checkpoint therapy": 1,
    "Coronary Artery Disease (ACS)": 1,
    "Endpoint validation in phase III oncology trials": 1,
    "COVID-19 prevention": 1,
    "Cross-disorder (Alzheimer's/Parkinson's/Epilepsy)": 1,
    "Obesity pharmacotherapy": 1,
    "Predictive factors for targeted therapy (CRC)": 1,
    "Adverse event epidemiology and predictors in phase III": 1,
    "Gene therapy for hemoglobinopathies": 1,
    "Retinal gene therapy": 1,
    "Long COVID": 1,
    "MASLD/NAFLD treatment": 1,
    "Autoimmune diseases (cross-disease)": 2,
    "Safety signal characterization in late-stage oncology trials": 1,
    "Microbiome-modifying exposures and ICI outcomes": 1,
    "Biomarkers (TNBC immunotherapy)": 1,
    "COVID-19 anticoagulation": 1,
    "Gene therapy for beta-thalassemia": 1,
    "Tumor microenvironment spatial immunology": 1,
    "Mechanisms of immunotherapy resistance": 1,
    "In vivo gene editing for amyloidosis": 1,
    "Atrial Fibrillation + Coronary Intervention": 1,
    "Surrogate endpoints and prognosis in clinical trials": 1,
    "Tumor microenvironment mechanisms": 1,
    "Type 2 diabetes injectable strategies": 1,
    "TMB and response to PD-1/PD-L1": 1
  },
  "question_types": {
    "efficacy_comparison": 80,
    "mechanism": 42,
    "review": 21,
    "prognosis": 31,
    "epidemiology": 26
  },
  "avg_tool_calls": 2.695,
  "avg_content_rubrics": 5.85,
  "generation_time": "2025-12-16T20:47:40.188920"
}